DNA demethylating agents suppress preclinical models of synovial sarcoma
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci190855 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Nobuhiko Hasegawa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics. Hauptthemen laut MEDLINE: Sarcoma, Synovial, Decitabine, DNA Methylation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Canadian Institutes.
Abstract (Originalsprache)
Synovial sarcoma is an aggressive soft-tissue cancer driven by the chimeric SS18::SSX fusion oncoprotein, which disrupts chromatin remodeling by combining two antagonistic transcriptional regulators. SS18 participates in BAF complexes that open chromatin, while the SSX genes are cancer-testis antigens that interface with chromatin decorated with monoubiquitinated histone H2A placed by polycomb repressive complex activity. Because KDM2B brings polycomb repressive complex to unmethylated CpG islands, it is plausible that methylation directly determines the distribution of SS18::SSX to target loci. Given that synovial sarcoma is also characterized by a peculiarly low DNA hypomethylation profile, we hypothesized that further disturbance of DNA methylation would have a negative impact on synovial sarcoma growth. DNMT1 disruption by CRISPR/Cas9 targeting or pharmacological inhibition with cytidine analogs 5-aza-2′-deoxycytidine (decitabine) and 5-azacytidine led to decreased genome-wide methylation, redistribution of SS18::SSX, and altered gene expression profiles, most prominently including upregulation of tumor suppressor genes, immune-related genes, and mesenchymal differentiation-related genes. These drugs suppressed growth of synovial sarcoma cell lines and drove cytoreduction in mouse genetic models. DNMT1 inhibitors, already approved for treating myelodysplastic syndromes, warrant further clinical investigation for synovial sarcoma as repurposed, targeted treatments exploiting a vulnerability in the intrinsic biology of this cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics.
- Department of Oncological Sciences.
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
- Department of Orthopaedics, Juntendo University, Faculty of Medicine, Tokyo, Japan.
- Hopp Children's Cancer Center, Heidelberg (KiTZ) Heidelberg, Germany.
- German Cancer Research Center (DKFZ), Heidelberg, Germany.
Förderung
- NCI NIH HHS
- National Cancer Institute
- Canadian Institutes
- JSPS
- DKFZ
- European Research Council
- MSK cancer center
Zitieren
APA
Hasegawa, N., Benabdallah, N. S., Smith-Fry, K., Li, L., McCollum, S., Li, J., Jones, C. A., Wagner, L., Dalal, V., Golde, V., Pejkovska, A., Carroll, L., Haldar, M., Pollack, S. M., Lowe, S. W., Nielsen, T. O., Banito, A., & Jones, K. B. (2025). DNA demethylating agents suppress preclinical models of synovial sarcoma. Journal of Clinical Investigation. https://doi.org/10.1172/jci190855
Vancouver
Hasegawa N, Benabdallah NS, Smith-Fry K, Li L, McCollum S, Li J, et al. DNA demethylating agents suppress preclinical models of synovial sarcoma. Journal of Clinical Investigation. 2025. doi:10.1172/jci190855
BibTeX
@article{Hasegawa2025,
author = {Hasegawa, Nobuhiko and Benabdallah, Nezha S and Smith-Fry, Kyllie and Li, Li and McCollum, Sarah and Li, Jinxiu and Jones, Caelen A and Wagner, Lena and Dalal, Vineet and Golde, Viola and Pejkovska, Anastasija and Carroll, Lara and Haldar, Malay and Pollack, Seth M and Lowe, Scott W and Nielsen, Torsten O and Banito, Ana and Jones, Kevin B},
title = {DNA demethylating agents suppress preclinical models of synovial sarcoma},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci190855}
}
EUVIMED